Login to Your Account


After years of taking a back seat to research efforts in indications such as cardiovascular disease, cancer and pulmonary disease, the gastrointestinal space is hot.

Having worked in academia, big pharma and venture capital, Naia Ltd. co-founder H. Daniel Perez got to witness drug development from three different perspectives, and he came away with one conclusion: "It was very clear things were not being done efficiently," he said.

Nohla Therapeutics Inc., a 2015 spin-off of the Fred Hutchinson Cancer Research Center, has a simply stated yet ambitious goal to create a “truly universal, off-the-shelf” ex vivo-expanded umbilical cord blood stem cell product.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: